title: Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
abstract: The aim was to compare the protective effects of pioglitazone (PIO) and/or liraglutide (LIRA) on β-cells with the progression of diabetes. Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage. In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage. In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage. Furthermore, β-cell mass was also increased by the treatment only in an early stage. Although there was no difference in apoptosis ratio between the two stages, β-cell proliferation was augmented by the treatment only in an early stage. In conclusion, protective effects of pioglitazone and/or liraglutide on β-cells were more powerful in an early stage of diabetes compared to an advanced stage.
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan. Electronic address: tomohiko@med.kawasaki-m.ac.jp.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Shimoda
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Hirukawa
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Seizo
authors.initials: S
authors.lastname: Okauchi
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kohara
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Sumiko
authors.initials: S
authors.lastname: Hamamoto
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan.
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Tawaramoto
authors.affiliation: Division of Diabetes and Endocrinology, Yodogawa Christian Hospital, 1-7-50 Shibajima, Osaka-city, Osaka 533-0024, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Hashiramoto
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, Okayama 701-0192, Japan; Department of General Internal Medicine 1, Kawasaki Hospital, Kawasaki Medical School, 2-1-80 Nakasange, Okayama-city, Okayama 700-8505, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Kaku
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D020169:Caspases / Q000235:genetics / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D018450:Disease Progression; D015870:Gene Expression / Q000187:drug effects; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D000069450:Liraglutide; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009929:Organ Size / Q000187:drug effects; D000077205:Pioglitazone; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D012337:RNA, Ribosomal, 18S / Q000235:genetics / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D012337:RNA, Ribosomal, 18S; D045162:Thiazolidinediones; D014280:Triglycerides; C052617:Bcl2 protein, mouse; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D020169:Caspases; D000077205:Pioglitazone
keywords: Cellular kinetics; Liraglutide; Pioglitazone; Progression of diabetic morbidity; β-Cell